Fiche publication
Date publication
mai 2025
Journal
Case reports in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LAMBERT Aurélien
Tous les auteurs :
Claessens A, Manchart A, Boufraine M, Guignard A, Bergeot A, Kieffer A, Lambert A
Lien Pubmed
Résumé
Ifosfamide, an alkylating agent, is used in treatment of various malignancies and may cause encephalopathies. The pathophysiology of this treatment adverse event is well documented, complex, and multifactorial, and involves the production of drug-related metabolites interfering with the normal functionality of neuronal synapses. Risk factors associated with the development of ifosfamide-induced encephalopathy have been identified including concurrent cisplatin administration and female gender. The clinical symptoms vary, ranging from simple confusion to seizure or coma. To date, no biomarkers have been evaluated in ifosfamide-induced encephalopathy. Neuron-specific enolase (NSE) elevation has already been correlated within toxic or metabolic encephalopathies regardless of the underlying etiology.
Mots clés
Adjuvant, Biomarkers, Chemotherapy, Iatrogenic disease, Ifosfamide, Osteosarcoma
Référence
Case Rep Oncol. 2025 05 28;18(1):800-808
